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Background: The aim was to confirm a previously defined prognostic index, combining a proliferation marker,
histological grade, and estrogen receptor (ER) in different subsets of primary N0/N1 chemo-naïve breast cancer
patients.
Methods/design: In the present study, including 1,854 patients, Ki67 was used in the index (KiGE), since it is the
generally accepted proliferation marker in clinical routine. The low KiGE-group was defined as histological grade 1
patients and grade 2 patients which were ER-positive and had low Ki67 expression. All other patients made up the
high KiGE-group. The KiGE-index separated patients into two groups with different prognosis. In multivariate
analysis, KiGE was significantly associated with disease-free survival, when adjusted for age at diagnosis, tumor size
and adjuvant endocrine treatment (hazard ratio: 3.5, 95% confidence interval: 2.6–4.7, P<0.0001).
Discussion: We have confirmed a prognostic index based on a proliferation marker (Ki67), histological grade, and
ER for identification of a low-risk group of patients with N0/N1 primary breast cancer. For this low-risk group
constituting 57% of the patients, with a five-year distant disease-free survival of 92%, adjuvant chemotherapy will
have limited effect and may be avoided.
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To predict clinical outcome and the effect of adjuvant sys-
temic treatment in breast cancer, recommendations such
as the St. Gallen breast cancer consensus guidelines
(Goldhirsch et al. 2011) and the Adjuvant! Online tool
(Ravdin et al. 2001) can be used. The development of
array-based technologies and sequencing of the human
genome (Perou et al. 2000; Sorlie et al. 2001; Paik et al.
2004; Sotiriou et al. 2006; Ivshina et al. 2006), provide add-
itional information beyond the traditional criteria used to
guide treatment decisions. This challenges the currently* Correspondence: Carina.strand@med.lu.se
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in any medium, provided the original work is pused factors, such as lymph node involvement, tumor size,
age, histological grade, human epidermal growth factor re-
ceptor 2 (HER2), Ki67, and estrogen (ER) and progester-
one receptor (PgR) status (Goldhirsch et al. 2011; Aebi
et al. 2011; Harris et al. 2007). At the St. Gallen Consensus
Meeting in 2011, OncotypeDXW was considered useful
for predicting responsiveness to chemotherapy in
an endocrine-responsive cohort, whereas other tests
were considered not yet fully validated. Two of the most
well-known gene-based assays, MammaPrintW and
OncotypeDXW have, however, also been questioned with
regard to their added prognostic value (Edén et al. 2004;
Cuzick et al. 2011). The ongoing clinical trials, MINDACT
and TAILORx, will hopefully provide more conclusive
data (Rutgers et al. 2011; Zujewski & Kamin 2008).n Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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esis and markers of proliferation have been shown to be
associated to prognosis and to effect of adjuvant and pal-
liative chemotherapy, to neoadjuvant endocrine therapy,
and to prognosis after adjuvant endocrine treatment
(Harris et al. 2007; Colozza et al. 2005; Beresford et al.
2006; De Azambuja et al. 2007; Goldhirsch et al. 2009;
Urruticoechea et al. 2005; Hietanen et al. 1995; Amadori
et al. 2008; Jones et al. 2009; Ellis et al. 2008; Viale et al.
2008). Ki67 is the marker of proliferation most widely
used (Goldhirsch et al. 2011; De Azambuja et al. 2007;
Urruticoechea et al. 2005; Dowsett et al. 2011; Luporsi
et al. 2012), but the role of other markers, such as cyclin
A (Bukholm et al. 2001; Michalides et al. 2002; Kuhling
et al. 2003; Baldini et al. 2006; Ahlin et al. 2009; Strand
et al. 2012) and phosphohistone H3 (Skaland et al. 2007),
remains under debate. Furthermore, global gene expres-
sion analyses have shown that proliferation-associated
genes seem to be among the most important for dividing
patients into groups with different prognosis, especially in
ER-positive and histological grade 2 breast cancers
(Sotiriou et al. 2006; Ivshina et al. 2006; Teschendorff
et al. 2007; Desmedt et al. 2008). In line with this, studies
from our group, as well as others, have shown that single
markers of proliferation (Ki67 and cyclin A) were of prog-
nostic importance in ER-positive breast cancer and in the
histological grade 2 (Strand et al. 2012; Klintman et al.
2010) and grade 1 (Aleskandarany et al. 2011) subgroups.
We have previously evaluated the importance of a prog-
nostic index based on the combination of cyclin A, histo-
logical grade, and ER (CAGE), in node-negative
premenopausal breast cancer patients (Strand et al. 2012).
The CAGE-index combined with HER2-status classified
53% of the women as low-risk patients with a five-year
distant disease-free survival (DDFS) of 95%. For this low-
risk group, adjuvant cytotoxic treatment will have limited
efficacy and may be avoided. In the present study, we
present data for Ki67. Importantly, avoiding unnecessary
use of chemotherapy for low-risk patients with N0/N1 pri-
mary breast cancer is also the primary aim of the
MINDACT and TAILORx trials (Rutgers et al. 2011;
Zujewski & Kamin 2008).
The aim of this study was to confirm a prognostic
index based on the combination of proliferation (Ki67),
histological grade, and ER (KiGE) in different subsets of
chemo-naïve patients with N0/N1 primary breast cancer
with special focus on five-year DDFS.
Materials and methods
Patients
We included 1,854 women with primary breast cancer
of which 1,522 originated from two randomized clinical
studies (Patient materials I–II) and three cohorts
(Patient materials III–V). The remaining 332 patientscame from a case–control study (Patient material VI).
Patients were excluded due to adjuvant chemotherapy
and/or missing information on adjuvant therapy, Ki67,
histological grade, or ER. Furthermore, for patients with
more than three positive lymph nodes, adjuvant chemo-
therapy is recommended (as stated in the St. Gallen
guidelines (Goldhirsch et al. 2011), hence these patients
were also excluded. The endpoint for the 1,522 patients
was defined as distant recurrence for 86% of the patients
(Patient materials I–II and IV–V) and as any recurrence
for the remaining 14% (Patient material III). Time to this
endpoint will hereafter be referred to as event-free sur-
vival. Median follow-up for patients alive and event-free
at last follow-up was 7.2 years (range: 1.1–17 years).
Only the first five years of follow-up were used in the
analyses.
Patient material I
SBII:2-pre (N=221, 68 distant recurrences). Premenopausal
women with stage II breast cancer were enrolled, between
1986 and 1991, in a randomized trial with the aim to com-
pare the effect of two years of tamoxifen (TAM) treatment
versus no adjuvant systemic treatment. The original trial
included 564 patients enrolled in the South and South-East
Swedish Health Care Regions (Rydén et al. 2005).
Patient material II
SBII:2-post (N=166, 22 distant recurrences). Postmeno-
pausal women with stage II breast cancer were enrolled,
between 1983 and 1991, in a randomized trial launched by
the Swedish Breast Cancer group of two versus five years
of adjuvant TAM (Swedish Breast Cancer Cooperative
Group 1996). The original trial included 1,107 patients
from the South Swedish Health Care Region. Paraffin em-
bedded tumor material has previously been collected from
a subgroup of patients treated with TAM for two years,
for comparison of a cytosol method and immunohisto-
chemistry for analyses of ER and PgR (Chebil et al. 2003).
In the present study, the paraffin embedded material was
used for analyses of Ki67 and HER2, and for the re-
evaluation of histological grade.
Patient material III
The Malmö cohort (N=217, 32 recurrences). The ori-
ginal cohort enrolled a consecutive series of 498 patients
diagnosed with primary breast cancer at the Department
of Pathology, Malmö University Hospital between 1988
and 1992. The purpose was to construct tissue
microarrays for biomarker evaluation (Borgquist et al.
2008).
Patient material IV
The Bone marrow metastases cohort (N=379, 27 distant
recurrences). The original study included 569 consecutive
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South Swedish Health Care Region and included patients
diagnosed between 1999 and 2003. The purpose was to
study the prognostic value of the presence of cytokeratin
positive cells in bone marrow aspirates from the sternum
(Falck et al. 2012).
Patient material V
The Odense cohort (N=539, 86 distant recurrences).
The original study enrolled a consecutive series of 841
patients with primary breast cancer referred to Odense
University Hospital, Denmark. Patients were enrolled
between 1980 and 1990 (Hansen et al. 2000). The pur-
pose was to collect a population-based cohort for evalu-
ation of prognostic factors.
All patients from these collections (Patient materials
I–V) were pooled in a database from which the follow-
ing subsets were extracted: Set 1: node-negative (N0), no
adjuvant therapy, ≤50 years at diagnosis (N=169, 20
events), Set 2: N0, no adjuvant therapy, >50 years at
diagnosis (N=488, 55 events), Set 3: node-positive (N1),
no adjuvant therapy (N=167, 39 events), Set 4: N0, adju-
vant endocrine therapy (N=291, 39 events), and Set 5:
N1, adjuvant endocrine therapy (N=407, 82 events)
(Table 1). The reason for the subdivision with regard to
age between Sets 1 and 2 was to confirm the index from
our original study (Strand et al. 2012) in a corresponding
subgroup with regard to menopausal status, adjuvant
therapy and lymph node status.
Patient material VI
The Uppsala study (N=166 cases and 166 controls,
Table 2). The original study included 900 patients diag-
nosed with primary breast cancer in the Uppsala-Örebro
region from 1993–2004. Exclusion criteria were tumor
size >50 mm, lymph node metastases or adjuvant
chemotherapy. Within this cohort, cases were defined as
women who died from breast cancer. Eligible as controls
were patients alive at the time of the corresponding
case’s death (Ahlin et al. 2009).
Biomarker analysis and definition of KiGE
ER, PgR, Ki67, HER2, and histological grade were ana-
lyzed and evaluated as described elsewhere (Ahlin et al.
2009; Rydén et al. 2005; Chebil et al. 2003; Borgquist
et al. 2008; Falck et al. 2012). If previously defined cut-
points were available, they were used in the present
study. Hence, cases above the median were considered
Ki67 high in Patient material V. Furthermore, Ahlin
et al. defined high Ki67 as cases above the seventh decile
of the empirical Ki67 distribution (which corresponded
to 20% positive cells) (Klintman et al. 2010) and there-
fore 20% was used for Patient materials I–IV and VI. For
Patient materials I–IV and VI, Ki67 was evaluated onTMAs and for Patient material V on whole tissue
sections. In order to confirm the combination of prolif-
eration, histological grade, and ER, the previously
applied index (CAGE) was used (Strand et al. 2012), but
cyclin A was replaced by Ki67, thereby creating KiGE.
The low KiGE-group was defined as histological grade 1
patients and grade 2 patients which were ER-positive
and had low Ki67 expression. High KiGE consisted of all
other patients.
Statistical methods
The Kaplan-Meier method was used to estimate event-
free survival and the Cox proportional hazards
model, stratified by patient material, was used for esti-
mation of hazard ratios (HR:s). Proportional hazards
assumptions were checked with Schoenfeld’s test
(Schoenfeld 1983). To avoid severe problems with
non-proportional hazards, the follow-up was re-
stricted to the first five years after diagnosis.
In Patient material VI, conditional logistic regression
analysis was used to estimate odds ratios (OR:s) and
confidence intervals (CI:s), using the proportional haz-
ards regression procedure in statistical analysis software
(SAS).
Forest plots were used to visualize HR:s and 95% CI:s
for the different subsets and the overall measure of
effect which was estimated using a DerSimonian-Laird
random-effects model.
All tests were two-sided. For evaluation of the
primary aim, the effect of the KiGE-index, P-values
<0.01 were considered significant. The statistical
analysis software Stata 12.1, 2012 (StataCorp, College
Station, TX) and SAS (SAS Institute, Inc.) were used
for statistical calculations. Whenever applicable, the
REMARK recommendations for reporting of tumor
marker studies were followed (McShane et al. 2005).
The study was approved by the ethics committee at
Lund University (LU 240-01).
Results
KiGE evaluation
Univariate analyses
The HR:s for high KiGE versus low KiGE, when each set
(Set 1–5) was analyzed separately, varied between 3.0
and 4.4, being statistically significant for all sets
(Figures 1a–e and 2a). When including all patients in
Set 1–5 (N=1,522, 235 events), a statistically significant
association between the combination variable KiGE and
event-free survival was found (HR: 3.9, 95% CI: 2.9–5.2,
P<0.0001; Figure 1f ).
In the case–control study (Patient material VI), there
was a statistically significant association between the
combination variable KiGE and breast cancer death (OR:
2.7, 95% CI: 1.7–4.3, P<0.0001).
Table 1 Patient and tumor characteristics
Factor Set 1 Set 2 Set 3 Set 4 Set 5 Total
No of patients 169 488 167 291 407 1,522
Events 20 55 39 39 82 235
Patient material Ia 30 9 66 39 77 221
Patient material IIa 0 0 0 67 99 166
Patient material IIIa 28 100 5 27 57 217
Patient material IVa 16 109 9 145 100 379
Patient material Va 95 270 87 13 74 539
Age median, years 45 65 53 61 61 60
Age range, years 28-50 50-90 27-93 30-88 33-89 27-93
Tumor size
≤ 20 mm 113 (67)b 364 (75) 68 (41) 115 (40) 208 (51) 868 (57)
>20 mm 56 (33) 124 (25) 99 (59) 176 (60) 199 (49) 654 (43)
Lymph nodes
Negative 169 488 0 291 0 948 (62)
1-3 positive 0 0 167 0 407 574 (38)
ER status
Positive 131 (78) 399 (82) 122 (73) 235 (81) 329 (81) 1,216 (80)
Negative 38 (22) 89 (18) 45 (27) 56 (19) 78 (19) 306 (20)
PgR status
Positive 46 (71) 121 (61) 56 (70) 168 (63) 200 (63) 591 (64)
Negative 19 (29) 76 (39) 24 (30) 100 (37) 118 (37) 337 (36)
Missing 104 291 87 23 89 594
Histological grade
1 41 (24) 136 (28) 19 (11) 32 (11) 67 (17) 295 (20)
2 82 (49) 250 (51) 97 (58) 166 (57) 233 (57) 828 (54)
3 46 (27) 102 (21) 51 (31) 93 (32) 107 (26) 399 (26)
Ki67
Low 109 (64) 343 (70) 111 (66) 210 (72) 315 (77) 1,088 (71)
Highc 60 (36) 145 (30) 56 (34) 81 (28) 92 (23) 434 (29)
HER2 status
Negative 54 (92) 142 (87) 62 (84) 216 (86) 249 (88) 723 (87)
Positived 5 (8) 21 (13) 12 (16) 36 (14) 33 (12) 107 (13)
Missing 110 325 93 39 125 692
Adjuvant endocrine treatment
Yes 0 0 0 291 407 698 (46)
No 169 488 167 0 0 824 (54)
Patient materials I-V were pooled in a database from which the following subsets were extracted: Set 1: node-negative (N0), no adjuvant therapy, ≤50 years at
diagnosis, Set 2: N0, no adjuvant therapy, >50 years at diagnosis, Set 3: node-positive (N1), no adjuvant therapy, Set 4: N0, adjuvant endocrine therapy, and Set 5:
N1, adjuvant endocrine therapy.
ER = estrogen receptor, PgR = progesterone receptor, HER2 = human epidermal growth factor 2.
aPatient material I (Rydén et al. 2005), Patient material II (Swedish Breast Cancer Cooperative Group 1996; Chebil et al. 2003), Patient material III (Borgquist et al.
2008), Patient material IV (Falck et al. 2012), and Patient material V (Hansen et al. 2000).
bNumbers in parentheses are percentages.
cHigh Ki67 was previously defined as cases above the seventh decile in the empirical Ki67 distribution (which corresponds to 20% positive cells) (Klintman et al.
2010) and 20% was used for Patient materials I-IV. Cases above the median were considered Ki67 high in Patient material V.
dHER2: positive if HER2-IHC 3+ or HER2-IHC 2+ and FISH amplified.
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The HR:s for KiGE for each of the five subsets, when ad-
justed for age at diagnosis and tumor size, were similar
compared to those without adjustment, as illustrated by
the forest plot (Figure 2b). When all subsets (Set 1–5)
were included, KiGE was significantly associated with
event-free survival, after adjustment for age at diagnosis,
tumor size, and adjuvant endocrine treatment (HR: 3.5,
95% CI: 2.6–4.7, P<0.0001). Including HER2 in the multi-
variate analysis (N=830, 133 events), KiGE remainedTable 2 Patient and tumor characteristics for the case–
control study (Patient material VI (Ahlin et al. 2009)
Factor Patient material VI
Case Control
No of patients 166 166
Age median, years 69 61
Age range, years 34-88 32-89
Tumor size
≤ 20 mm 102 (61)a 131 (79)
>20 mm 64 (39) 35 (21)
Lymph nodes
Negative 166 166
ER status
Positive 94 (57) 131 (79)
Negative 72 (43) 35 (21)
PgR status
Positive 69 (42) 113 (68)
Negative 96 (58) 53 (32)
Missing 1 0
Histological grade
1 14 (8) 39 (23)
2 85 (51) 94 (57)
3 67 (41) 33 (20)
Ki67
Low 87 (52) 112 (67)
Highb 79 (48) 54 (33)
HER2 status
Negative 145 (91) 143 (92)
Positivec 14 (9) 13 (8)
Missing 7 10
Adjuvant endocrine treatment
Yes 48 (29) 40 (24)
No 118 (71) 126 (76)
ER = estrogen receptor, PgR = progesterone receptor, HER2 = human
epidermal growth factor 2.
aNumbers in parentheses are percentages.
bHigh Ki67 was defined as cases with more than 20% positive cells.
cHER2: positive if HER2-IHC 3+ or HER2-IHC 2+ and FISH amplified.significantly associated with event-free survival (HR: 4.0,
95% CI: 2.7–6.0, P<0.0001).
In the case–control study, KiGE was significantly
associated with breast cancer death, after adjustment
for age at diagnosis, tumor size, and adjuvant endo-
crine treatment (OR: 3.2, 95% CI: 1.8–5.5, P<0.0001).
Subset analyses of Ki67 in patients not treated with
adjuvant tamoxifen (Set 1–3)
Ki67 in ER-positive versus ER-negative cases
In order to confirm results from previous investiga-
tions (Teschendorff et al. 2007; Desmedt et al. 2008;
Klintman et al. 2010) showing that the prognostic im-
portance of Ki67 is dependent on ER-status, subgroup
analyses were performed, stratified by ER-status. In
univariate analyses, Ki67 was a significant prognostic
factor in the ER-positive subgroup (HR: 3.3, 95% CI:
2.0–5.5, P<0.0001; N=652, 76 events), but not in the
ER-negative subgroup (HR: 1.0, 95% CI: 0.49–2.1,
P=0.96; N=172, 38 events). The difference in prog-
nostic importance of Ki67 between ER-positive and
ER-negative cases was further analyzed in a Cox
model allowing for interaction between the two fac-
tors. The interaction effect, corresponding to the
ratio of the HR:s for Ki67 in the ER-positive and
ER-negative subgroups, was 2.7 (95% CI: 1.2–6.1,
P=0.02).
Ki67 in histological grade subgroups
Previous studies have demonstrated that the prognostic
importance of Ki67 is mainly attributed to the histo-
logical grade 2 subgroup (Klintman et al. 2010;
Aleskandarany et al. 2011). Similar trends were seen in
the present study. In the histological grade 2 tumors
(N=429, 51 events), the HR for high versus low Ki67 was
1.8 (95% CI: 1.0–3.4, P=0.05). The five-year event-free
survival figures were 82% (95% CI: 73–88%) for high
Ki67 and 90% (95% CI: 86–93%) for low Ki67, respect-
ively. There were too few events (N=196, 5 events) to
draw any conclusions on the impact of Ki67 in the histo-
logical grade 1 subgroup. The five-year event-free sur-
vival in the histological grade 1 subgroup was 97% (95%
CI: 93–99%), independent of Ki67. Ki67 was not a sig-
nificant prognostic factor in the histological grade 3 sub-
group (HR: 1.0, 95% CI: 0.56–1.9, P=0.91; N=199, 58
events), with five-year DDFS of 73% (95% CI: 64–79%)
and 65% (95% CI: 52–76%) for high and low Ki67
groups, respectively.
Five-year DDFS for high and low KiGE (Patient materials
I–II and IV–V)
Use of the KiGE-index in the N0/N1-subgroup with
information on distant recurrences (N=1,305, 203
distant recurrences) identified a low-risk group
HR: 4.4, 95% CI: 1.4-13
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Figure 1 Kaplan-Meier survival estimates of event-free survival, and hazard ratios (HR) with corresponding 95% confidence intervals
(CI) for the different subsets (1a-e), stratified by patient material, and for all the patients (1f). From Patient materials I-V the following
subsets were extracted: Set 1: node-negative (N0), no adjuvant therapy, ≤50 years at diagnosis (1a), Set 2: N0, no adjuvant therapy, >50 years at
diagnosis (1b), Set 3: node-positive (N1), no adjuvant therapy (1c), Set 4: N0, adjuvant endocrine therapy (1d), and Set 5: N1, adjuvant endocrine
therapy (1e). Event-free survival corresponds to distant disease-free survival for Patient materials I-II and IV-V, and to recurrence-free survival for
Patient material III.
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DDFS of 92% (95% CI: 89–93%). The DDFS for the
remaining 43% of the patients was 73% (95% CI: 69–
77%). The association between the KiGE-index and
DDFS was statistically significant (HR: 3.4, 95% CI:
2.5–4.6, P<0.0001; Figure 3).
In the N0-subgroup (N=793, 97 distant recurrences),
the KiGE-index identified a low-risk group constituting
57% of the patients with a five-year DDFS of 93% (95%
CI: 90–95%; HR: 3.2, 95% CI: 2.0–4.9, P<0.0001).
Equally, in the N1-subgroup (N=512, 106 distant recur-
rences), the KiGE-index identified a low-risk group of
similar size (56%) with a five-year DDFS of 89% (95% CI:
85–92%; HR: 3.7, 95% CI: 2.4–5.7, P<0.0001).Discussion
This confirmation study for N0/N1 chemo-naïve breast
cancer patients, confirms the prognostic value of a previ-
ously defined index combining proliferation (previously
cyclin A, in the present study Ki67), histological grade,
and ER. Importantly, the KiGE-index separated chemo-
naïve patients into groups with different risk, independ-
ent of menopausal status, lymph node status, and
whether endocrine adjuvant treatment was given or not.
The robustness of the index is strengthened by the fact
that the evaluation of Ki67, histological grade, and ER
was performed in different studies by different persons
using different cut-points, that studies from three
Swedish health care regions and one Danish region were
a)
Overall effect
Set 5
Set 4
Set 3
Set 2
Set 1
1/2 1 2 4 8 16 32
HR and 95% CI
b)
Overall effect
Set 5
Set 4
Set 3
Set 2
Set 1
1/2 1 2 4 8 16 32
HR and 95% CI
Figure 2 Forest plots for the different subsets, showing hazard ratios (HR:s) with corresponding 95% confidence intervals (CI:s) for
KiGE in univariate analysis (a) and in multivariate analysis (b), adjusted for age at diagnosis and tumor size. The diamonds and the
vertical dashed lines represent the overall measures of effect. The areas of the grey squares are proportional to each subset’s weight in
the meta-analysis.
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were used (randomized, cohort and case-control stud-
ies). Furthermore, when analyzing Patient materials I–V
separately (not the five sets), KiGE remained a signifi-
cant prognostic factor (HR:s varied between 2.1 and 9.0)
in all but one patient material (Patient material II,
P=0.09; data not shown). We were also able to confirm
the previous finding that the prognostic value of
Ki67 is limited to ER-positive breast cancer and is
most pronounced for the histological grade 2 subgroup.
The latter findings are furthermore in line with geneexpression analyses (Sotiriou et al. 2006; Ivshina et al.
2006; Teschendorff et al. 2007; Desmedt et al. 2008).
However, a recent publication (Munzone et al. 2012)
showed that within the group of patients with node-
negative triple-negative breast cancer, Ki67 was associ-
ated with different prognosis when using a higher
cut-point (35%). The KiGE-index is similar to the index
proposed at the St. Gallen consensus meeting in 2011
(Goldhirsch et al. 2011), with Ki67 separating clinico-
pathologically classified ‘Luminal’ ER-positive breast can-
cer into ‘Luminal A’ and ‘Luminal B’ subgroups with
HR: 3.4, 95% CI: 2.5-4.6
P <0.0001
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Figure 3 Five-year DDFS by the KiGE-index in N0/N1 chemo-
naïve breast cancer patients.
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of therapy. Chemotherapy, with or without anti-HER2
therapy, is suggested for the ‘Luminal B’ subgroup, but
not for the ‘Luminal A’ subgroup (Goldhirsch et al.
2011). According to the St. Gallen guidelines, not taking
histological grade into consideration, patients with ER-
positive low proliferating (and HER2 normal) tumors
will be classified as having ‘Luminal A’ breast cancer.
According to the KiGE-index, with the inclusion of
histological grade, some of these patients will instead be
considered as having worse prognosis. In this large pa-
tient material, patients with ER-positive, low Ki67, and
histological 3 breast cancer (N=42) have a poor progno-
sis, with a five-year DDFS of 64% (95% CI: 47–76%).
This subgroup constituted 6% (42/652) of the ER-
positive (chemo-naïve) patients in our study (Patient ma-
terials I–V). In a recent publication by the International
Ki67 in Breast Cancer Working Group (Dowsett et al.
2011), certain important drawbacks for Ki67 analyses
were highlighted, including number of cancer cells being
scored and cut-point used. Furthermore, the distribution
of Ki67 values makes it difficult to define a cut-point.
The inherent drawbacks with the evaluation of Ki67 may
at least partly be overcome by also considering histo-
logical grade, as suggested in the present study. Our
study was, probably due to low power, unable to demon-
strate any prognostic importance of Ki67 in histological
grade 1 breast cancer. Aleskandarany et al. however,
demonstrated that patients with high Ki67 had a signifi-
cantly worse prognosis than those with low Ki67, in a
large study, including 494 histological grade 1 breast
cancers (Aleskandarany et al. 2011). Therefore, we do
not exclude the possibility that Ki67 has prognostic
value in the histological grade 1 subgroup.
Identifying a subgroup of patients not in need of adju-
vant chemotherapy, was found to be the top priority on
a list of the most urgent research areas in breast cancerin a recent web-consultant study (Dowsett et al. 2007).
The Early Breast Cancer Trialists´ Collaborative Group
(Peto et al. 2012) demonstrated that the effect of chemo-
therapy was independent of age, node status, tumor size,
differentiation, ER-status, and tamoxifen use. However,
information on quantitative immunohistochemistry of
proliferation was not included. Ki67 combined with
ER-status and histological grade may be helpful in this
respect. Breast cancer patients with histological grade 1
tumors or patients with ER-positive and histological
grade 2 tumors with low Ki67 expression constitute 57%
of the patients with N0/N1 cancers in this study, with a
five-year DDFS of 92%. Adjuvant chemotherapy would
have limited added value for this group. The identifica-
tion of a low-risk group not in need of adjuvant chemo-
therapy is also the primary aim of two ongoing clinical
trials (MINDACT and TAILORx) (Rutgers et al. 2011;
Zujewski & Kamin 2008) evaluating the gene profiles
MammaPrintW and OncotypeDXW. The MINDACT trial
(Rutgers et al. 2011) is a prospective, randomized trial
using the 70-gene signature (MammaPrintW) together
with the common clinical-pathological criteria for
selecting patients for adjuvant chemotherapy. It is being
tested in patients with N0/N1 breast cancer. MINDACT
has a null hypothesis of a five-year distant metastasis-
free survival of 92%, which will be tested for the group
of patients who have a low-risk gene prognosis signature
and high clinical-pathological criteria, and who were
randomized to use the 70-gene signature and thus re-
ceive no chemotherapy. In a pilot phase based on the
first 800 patients from this trial, the low-risk group con-
stituted 65% (Rutgers et al. 2011). This figure is in line
with 57% being the percentage of low-risk patients in
our study, who furthermore had the same five-year
DDFS as the null hypothesis in the MINDACT trial
(92%). Risk group stratification may be further modified
by also considering other established prognostic factors,
e.g. lymph node status, tumor size, age, and HER2-
status. The incidence of recurrences in the low-risk
group could thereby be further decreased, but with the
consequence of a smaller low-risk group.
In conclusion, we have confirmed a prognostic
index based on proliferation (Ki67), histological grade,
and ER for identifying a low-risk group of patients
with N0/N1 breast cancer. For this large low-risk
group, with a five-year DDFS of 92%, adjuvant
chemotherapy will have limited effect and may thus
be avoided.
Competing interest
The authors have no conflicts of interest to declare.
Authors’ contributions
CS, MK, POB, PM and MF were responsible for concept and design of the
study. Financial and administrative support was provided by MF. MB, SB, GC,
AKF, MLF, DG, KJ, MK, PM, HO, LR and OS provided study material and
Strand et al. SpringerPlus 2013, 2:111 Page 9 of 10
http://www.springerplus.com/content/2/1/111information of patients. CS, DG, IH, PM, POB and MF were responsible of
data analysis and interpretation. CS, MF and POB were responsible for the
manuscript writing. All authors read and approved the final version of the
manuscript.
Acknowledgments
We are indebted to participating departments of the South and South-East
Swedish Breast Cancer Groups, of the Uppsala-Örebro region, and of the
Odense region for providing samples and clinical follow-up. We thank
Kristina Lövgren for technical skills in creating the TMA blocks and Marit
Holmqvist for statistical analysis of the case–control study.
Funding
This work was supported by funding from the Swedish Cancer Society, the
Swedish Research Council, the Gunnar Nilsson Cancer Foundation, the Mrs.
Berta Kamprad Foundation, the Anna and Edwin Bergers foundation, the
Swedish Breast Cancer Association (BRO), the Skåne University Hospital
Research Foundation, the Skåne County Council’s Research and
Development Foundation, and Governmental Funding of Clinical Research
within the National Health Service.
Author details
1Lund University, Division of Oncology, Department of Clinical Sciences
Lund, Skåne University Hospital, Barngatan 2B, SE-221 85, Lund, Sweden.
2Department of Pathology, Odense University Hospital, DK-5000, Odense,
Denmark. 3Unilabs, Mammography, Bergaliden SE-252 23, Helsingborg,
Sweden. 4Department of Surgery, Helsingborg Hospital, SE-281 85,
Helsingborg, Sweden. 5Uppsala University, Department of Oncology,
Radiology and Clinical Immunology, SE-751 85, Uppsala, Sweden. 6Lund
University, Department of Pathology, Skåne University Hospital, SE-221 85,
Lund, Sweden. 7Division of Pathology, Department of Clinical Sciences Lund,
Lund University, SE-221 85, Lund, Sweden. 8Skåne Department of Oncology,
Skåne University Hospital, SE-221 85, Lund, Sweden. 9Department of Clinical
and Experimental Medicine, Faculty of Health Sciences, Department of
Clinical Pathology and Clinical Genetics, County Council of Östergötland,
Linköping University, Molecular and Immunological Pathology, SE-581 91,
Linköping, Sweden. 10Lund University, Division of Surgery, Department of
Clinical Sciences Lund, Skåne University Hospital, SE-221 85, Lund, Sweden.
11Linköping University, Division of Oncology, Department of Clinical and
Experimental Medicine, Faculty of Health Sciences, County Council of
Östergötland, SE-581 85, Linköping, Sweden.
Received: 28 February 2013 Accepted: 4 March 2013
Published: 14 March 2013
References
Aebi S, Davidson T, Gruber G, Cardoso F (2011) Primary breast cancer: ESMO
Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann
Oncol Offic J Eur Soc Med Oncol/ESMO 22(Suppl 6):vi12–24.
Ahlin C, Zhou W, Holmqvist M, Holmberg L, Nilsson C, Jirstrom K, Blomqvist C,
Amini RM, Fjallskog ML (2009) Cyclin A is a proliferative marker with good
prognostic value in node-negative breast cancer. Canc Epidemiol Biomark
Prev Publ Am Assoc Canc Res Cosponsored Am Soc Prev Oncol 18(9):2501–
2506.
Aleskandarany MA, Rakha EA, Macmillan RD, Powe DG, Ellis IO, Green AR (2011)
MIB1/Ki-67 labelling index can classify grade 2 breast cancer into two
clinically distinct subgroups. Breast Cancer Res Treat 127(3):591–599.
Amadori D, Nanni O, Volpi A, Casadei Giunchi D, Marangolo M, Livi L, Ravaioli A,
Rossi AP, Gambi A, Luzi Fedeli S, Perroni D, Scarpi E, Becciolini A, Silvestrini R
(2008) Phase III randomized multicenter study on the effects of adjuvant
CMF in patients with node-negative, rapidly proliferating breast cancer:
twelve-year results and retrospective subgroup analysis. Breast Cancer Res
Treat 108(2):259–264.
Baldini E, Camerini A, Sgambato A, Prochilo T, Capodanno A, Pasqualetti F,
Orlandini C, Resta L, Bevilacqua G, Collecchi P (2006) Cyclin A and E2F1
overexpression correlate with reduced disease-free survival in node-negative
breast cancer patients. Anticancer Res 26(6B):4415–4421.
Beresford MJ, Wilson GD, Makris A (2006) Measuring proliferation in breast
cancer: practicalities and applications. Breast Cancer Res 8(6):216.
Borgquist S, Holm C, Stendahl M, Anagnostaki L, Landberg G, Jirstrom K (2008)
Oestrogen receptors alpha and beta show different associations toclinicopathological parameters and their co-expression might predict a
better response to endocrine treatment in breast cancer. J Clin Pathol
61(2):197–203.
Bukholm IR, Bukholm G, Nesland JM (2001) Over-expression of cyclin A is highly
associated with early relapse and reduced survival in patients with primary
breast carcinomas. Int J Canc J Int Canc 93(2):283–287.
Chebil G, Bendahl PO, Idvall I, Ferno M (2003) Comparison of
immunohistochemical and biochemical assay of steroid receptors in primary
breast cancer–clinical associations and reasons for discrepancies. Acta Oncol
42(7):719–725.
Colozza M, Azambuja E, Cardoso F, Sotiriou C, Larsimont D, Piccart MJ (2005)
Proliferative markers as prognostic and predictive tools in early breast cancer:
where are we now? Ann Oncol 16(11):1723–1739.
Cuzick J, Dowsett M, Pineda S, Wale C, Salter J, Quinn E, Zabaglo L, Mallon E,
Green AR, Ellis IO, Howell A, Buzdar AU, Forbes JF (2011) Prognostic value of
a combined estrogen receptor, progesterone receptor, Ki-67, and human
epidermal growth factor receptor 2 immunohistochemical score and
comparison with the Genomic Health recurrence score in early breast cancer.
J Clin Oncol 29(32):4273–4278.
De Azambuja E, Cardoso F, de Castro G Jr, Colozza M, Mano MS, Durbecq V,
Sotiriou C, Larsimont D, Piccart-Gebhart MJ, Paesmans M (2007) Ki-67 as
prognostic marker in early breast cancer: a meta-analysis of published studies
involving 12,155 patients. Br J Cancer 96(10):1504–1513.
Desmedt C, Haibe-Kains B, Wirapati P, Buyse M, Larsimont D, Bontempi G, Delorenzi M,
Piccart M, Sotiriou C (2008) Biological processes associated with breast cancer
clinical outcome depend on the molecular subtypes. Clin Cancer Res 14(16):5158–
5165.
Dowsett M, Goldhirsch A, Hayes DF, Senn HJ, Wood W, Viale G (2007)
International Web-based consultation on priorities for translational breast
cancer research. Breast Cancer Res 9(6):81.
Dowsett M, Nielsen TO, A'Hern R, Bartlett J, Coombes RC, Cuzick J, Ellis M, Henry
NL, Hugh JC, Lively T, McShane L, Paik S, Penault-Llorca F, Prudkin L, Regan
M, Salter J, Sotiriou C, Smith IE, Viale G, Zujewski JA, Hayes DF (2011)
Assessment of Ki67 in breast cancer: recommendations from the
International Ki67 in Breast Cancer working group. J Natl Cancer Inst
103(22):1656–1664.
Eden P, Ritz C, Rose C, Ferno M, Peterson C (2004) "Good Old" clinical markers
have similar power in breast cancer prognosis as microarray gene expression
profilers. Eur J Cancer 40(12):1837–1841.
Ellis MJ, Tao Y, Luo J, A'Hern R, Evans DB, Bhatnagar AS, Chaudri Ross HA, von
Kameke A, Miller WR, Smith I, Eiermann W, Dowsett M (2008) Outcome
prediction for estrogen receptor-positive breast cancer based on
postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst
100(19):1380–1388.
Falck AK, Bendahl PO, Ingvar C, Isola J, Jonsson PE, Lindblom P, Lovgren K,
Rennstam K, Ferno M, Rydén L (2012) Analysis of and prognostic information
from disseminated tumour cells in bone marrow in primary breast cancer: a
prospective observational study. BMC Cancer 12(1):403.
Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B, Senn HJ (2009)
Thresholds for therapies: highlights of the St Gallen International Expert
Consensus on the primary therapy of early breast cancer 2009. Ann
Oncol 20(8):1319–1329.
Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ
(2011) Strategies for subtypes--dealing with the diversity of breast
cancer: highlights of the St Gallen International Expert Consensus on the
Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22(8):1736–1747.
Hansen S, Grabau DA, Sorensen FB, Bak M, Vach W, Rose C (2000) The
prognostic value of angiogenesis by Chalkley counting in a confirmatory
study design on 836 breast cancer patients. Clin Canc Res Offic J Am
Assoc Canc Res 6(1):139–146.
Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes
DF, Bast RC Jr (2007) American Society of Clinical Oncology 2007 update of
recommendations for the use of tumor markers in breast cancer. J Clin
Oncol 25(33):5287–5312.
Hietanen P, Blomqvist C, Wasenius VM, Niskanen E, Franssila K, Nordling S (1995)
Do DNA ploidy and S-phase fraction in primary tumour predict the response
to chemotherapy in metastatic breast cancer? Br J Cancer 71(5):1029–1032.
Ivshina AV, George J, Senko O, Mow B, Putti TC, Smeds J, Lindahl T, Pawitan Y,
Hall P, Nordgren H, Wong JE, Liu ET, Bergh J, Kuznetsov VA, Miller LD (2006)
Genetic reclassification of histologic grade delineates new clinical subtypes
of breast cancer. Cancer Res 66(21):10292–10301.
Strand et al. SpringerPlus 2013, 2:111 Page 10 of 10
http://www.springerplus.com/content/2/1/111Jones RL, Salter J, A'Hern R, Nerurkar A, Parton M, Reis-Filho JS, Smith IE, Dowsett
M (2009) The prognostic significance of Ki67 before and after neoadjuvant
chemotherapy in breast cancer. Breast Cancer Res Treat 116(1):53–68.
Klintman M, Bendahl PO, Grabau D, Lovgren K, Malmstrom P, Ferno M (2010) The
prognostic value of Ki67 is dependent on estrogen receptor status and
histological grade in premenopausal patients with node-negative breast
cancer. Mod Pathol 23(2):251–259.
Kuhling H, Alm P, Olsson H, Ferno M, Baldetorp B, Parwaresch R, Rudolph P
(2003) Expression of cyclins E, A, and B, and prognosis in lymph node-
negative breast cancer. J Pathol 199(4):424–431.
Luporsi E, Andre F, Spyratos F, Martin PM, Jacquemier J, Penault-Llorca F,
Tubiana-Mathieu N, Sigal-Zafrani B, Arnould L, Gompel A, Egele C, Poulet B,
Clough KB, Crouet H, Fourquet A, Lefranc JP, Mathelin C, Rouyer N, Serin D,
Spielmann M, Haugh M, Chenard MP, Brain E, de Cremoux P, Bellocq JP
(2012) Ki-67: level of evidence and methodological considerations for its role
in the clinical management of breast cancer: analytical and critical review.
Breast Cancer Res Treat 132(3):895–915.
McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2005)
Reporting recommendations for tumor marker prognostic studies (REMARK).
J Natl Cancer Inst 97(16):1180–1184.
Michalides R, van Tinteren H, Balkenende A, Vermorken JB, Benraadt J, Huldij J,
van Diest P (2002) Cyclin A is a prognostic indicator in early stage breast
cancer with and without tamoxifen treatment. Br J Cancer 86(3):402–408.
Munzone E, Botteri E, Sciandivasci A, Curigliano G, Nole F, Mastropasqua M,
Rotmensz N, Colleoni M, Esposito A, Adamoli L, Luini A, Goldhirsch A, Viale G
(2012) Prognostic value of Ki-67 labeling index in patients with node-
negative, triple-negative breast cancer. Breast Cancer Res Treat 134(1):
277–282.
Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson
D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N (2004) A
multigene assay to predict recurrence of tamoxifen-treated, node-negative
breast cancer. N Eng J Med 351(27):2817–2826.
Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross
DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX,
Lonning PE, Borresen-Dale AL, Brown PO, Botstein D (2000) Molecular
portraits of human breast tumours. Nature 406(6797):747–752.
Peto R, Davies C, Godwin J, Gray R, Pan HC, Clarke M, Cutter D, Darby S, McGale
P, Taylor C, Wang YC, Bergh J, Di Leo A, Albain K, Swain S, Piccart M,
Pritchard K (2012) Comparisons between different polychemotherapy
regimens for early breast cancer: meta-analyses of long-term outcome
among 100,000 women in 123 randomised trials. Lancet 379(9814):432–444.
Ravdin PM, Siminoff LA, Davis GJ, Mercer MB, Hewlett J, Gerson N, Parker HL
(2001) Computer program to assist in making decisions about adjuvant
therapy for women with early breast cancer. J Clin Oncol 19(4):980–991
Rutgers E, Piccart-Gebhart MJ, Bogaerts J, Delaloge S, Veer LV, Rubio IT, Viale G,
Thompson AM, Passalacqua R, Nitz U, Vindevoghel A, Pierga JY, Ravdin PM,
Werutsky G, Cardoso F (2011) The EORTC 10041/BIG 03-04 MINDACT trial is
feasible: results of the pilot phase. Eur J Cancer 47(18):2742–2749.
Rydén L, Jonsson PE, Chebil G, Dufmats M, Ferno M, Jirstrom K, Kallstrom AC,
Landberg G, Stal O, Thorstenson S, Nordenskjold B (2005) Two years of
adjuvant tamoxifen in premenopausal patients with breast cancer: a
randomised, controlled trial with long-term follow-up. Eur J Cancer
41(2):256–264.
Schoenfeld DA (1983) Sample-size formula for the proportional-hazards
regression model. Biometrics 39(2):499–503.
Skaland I, Janssen EA, Gudlaugsson E, Klos J, Kjellevold KH, Soiland H, Baak JP
(2007) Phosphohistone H3 expression has much stronger prognostic value
than classical prognosticators in invasive lymph node-negative breast cancer
patients less than 55 years of age. Mod Pathol 20(12):1307–1315.
Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB,
van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein
D, Eystein Lonning P, Borresen-Dale AL (2001) Gene expression patterns of
breast carcinomas distinguish tumor subclasses with clinical implications.
Proc Natl Acad Sci USA 98(19):10869–10874.
Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, Nordgren H, Farmer P, Praz
V, Haibe-Kains B, Desmedt C, Larsimont D, Cardoso F, Peterse H, Nuyten D,
Buyse M, Van de Vijver MJ, Bergh J, Piccart M, Delorenzi M (2006) Gene
expression profiling in breast cancer: understanding the molecular basis of
histologic grade to improve prognosis. J Natl Cancer Inst 98(4):262–272.
Strand C, Ahlin C, Bendahl PO, Fjallskog ML, Hedenfalk I, Malmstrom P, Ferno M
(2012) Combination of the proliferation marker cyclin A, histological grade,and estrogen receptor status in a new variable with high prognostic impact
in breast cancer. Breast Cancer Res Treat 131(1):33–40.
Swedish Breast Cancer Cooperative Group (1996) Randomized trial of two versus
five years of adjuvant tamoxifen for postmenopausal early stage breast
cancer. Swedish Breast Cancer Cooperative Group. J Natl Cancer Inst 88
(21):1543–1549.
Teschendorff AE, Miremadi A, Pinder SE, Ellis IO, Caldas C (2007) An immune
response gene expression module identifies a good prognosis subtype in
estrogen receptor negative breast cancer. Genome Biol 8(8):157.
Urruticoechea A, Smith IE, Dowsett M (2005) Proliferation marker Ki-67 in early
breast cancer. J Clin Oncol 23(28):7212–7220.
Viale G, Regan MM, Mastropasqua MG, Maffini F, Maiorano E, Colleoni M, Price
KN, Golouh R, Perin T, Brown RW, Kovacs A, Pillay K, Ohlschlegel C, Gusterson
BA, Castiglione-Gertsch M, Gelber RD, Goldhirsch A, Coates AS (2008)
Predictive value of tumor Ki-67 expression in two randomized trials of
adjuvant chemoendocrine therapy for node-negative breast cancer. J Natl
Cancer Inst 100(3):207–212.
Zujewski JA, Kamin L (2008) Trial assessing individualized options for treatment
for breast cancer: the TAILORx trial. Future Oncol 4(5):603–610.
doi:10.1186/2193-1801-2-111
Cite this article as: Strand et al.: The combination of Ki67, histological
grade and estrogen receptor status identifies a low-risk group among
1,854 chemo-naïve women with N0/N1 primary breast cancer.
SpringerPlus 2013 2:111.Submit your manuscript to a 
journal and beneﬁ t from:
7 Convenient online submission
7 Rigorous peer review
7 Immediate publication on acceptance
7 Open access: articles freely available online
7 High visibility within the ﬁ eld
7 Retaining the copyright to your article
    Submit your next manuscript at 7 springeropen.com
